#USA #Chicago #Cancer Research #ADC technology #Acepodia

Acepodia Unveils Preclinical Progress at 2025 AACR Meeting

On April 21, 2025, Acepodia Inc., a leading clinical-stage biotechnology company headquartered in Taipei and Alameda, California, made headlines with its announcement regarding the presentation of new preclinical data. This data not only showcases the company’s innovative capabilities but also brings attention to their proprietary dual-payload antibody-drug conjugate (AD2C) technology, particularly aimed at targeting hepatocellular carcinoma (HCC). The findings will be prominently featured at the American Association for Cancer Research (AACR) Annual Meeting 2025 held from April 25 to April 30 in Chicago, Illinois.

The poster, titled "Development of Dual-Payload Anti-GPC3 Antibody-Drug Conjugate by Dual-Payload Antibody Conjugation (AD2C) Platform for Hepatocellular Carcinoma Treatment," presents a significant evolution in Antibody-Drug Conjugates (ADCs) that Acepodia is developing using their AD2C platform. Acepodia's AD2C technology is remarkable in its ability to conjugate two distinct therapeutic payloads to a single antibody, eliminating the traditional reliance on antibody engineering or enzymatic conjugation methods. By utilizing this dual-payload approach, Acepodia aims to enhance the therapeutic efficacy through improved targeting of diverse cell populations within heterogeneous tumors, overcoming the limitations that frequently accompany single-payload therapies.

Dr. Sonny Hsiao, Chairman and CEO of Acepodia, highlighted the significance of this innovation, stating, "Acepodia's dual-payload ADC approach is designed to address key limitations of current single-payload therapies. By combining targeted delivery with enhanced cytotoxicity, this platform holds promise for more effective treatment of liver cancer and other solid tumors." This perspective emphasizes the dual role of AD2C in facilitating targeted medicine while also offering greater potency, potentially transforming current cancer treatment paradigms.

The presentation specifics are as follows:

• - Session Title: Novel Drug Delivery Technologies
• - Session Category: Experimental and Molecular Therapeutics
• - Date and Time: April 28, 2025, from 9:00 AM to 12:00 PM CDT
• - Location: McCormick Place Convention Center, Chicago, IL
• - Poster Board Number: 4 | Poster Section 23
• - Abstract Number: 1785

This development is part of a broader portfolio of Acepodia's innovative conjugation technologies that stem from the groundbreaking research of Nobel Laureate Dr. Carolyn Bertozzi. The implementation of bioorthogonal click chemistry allows for precise delivery of these therapeutic payloads, thereby creating a unique therapeutic potential tailored for various cancer types and autoimmune diseases.

Acepodia's Vision for Cancer Treatment

Acepodia’s focus extends beyond merely addressing existing treatment gaps. It aims to revolutionize the way we approach cancer therapies. The dual-payload ADCs developed through the AD2C platform not only provide a novel mechanism for combating tumor heterogeneity but also equip healthcare providers with advanced tools to tackle drug resistance in patients.

As the AACR Annual Meeting approaches, anticipation builds around not just Acepodia's contributions but also the implications of their work on global cancer treatment methodologies. The world watches as Acepodia positions itself not just as a participant in the biotechnology field, but as a potential game-changer in cancer therapeutics.

For additional insights into Acepodia’s advancements and upcoming projects, visit their official website at www.acepodia.com.